Ethylmethylhydroxypyridine succinate
Symptoms: drowsiness and sedation may occur. Due to the low toxicity, overdose is unlikely.
Treatment: as a rule, it is not required — the symptoms disappear on their own within a day. In severe cases of insomnia — nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.
Pyridoxine
Symptoms: taking high doses of pyridoxine for a short period of time (at a dose of more than 1 g/day) can lead to short-term neurotoxic effects.
Treatment: when taking pyridoxine at a dose exceeding 150 mg/kg, it is recommended to induce vomiting and take activated charcoal. Provocation of vomiting is most effective during the first 30 minutes after taking the drug. Emergency measures may be required.
hypersensitivity,
acute hepatic and / or renal insufficiency,
pregnancy,
lactation,
children's age.
With caution: peptic ulcer of the stomach and duodenum.
Ethylmethylhydroxypyridine succinate
Increases the effect of benzodiazepine anxiolytics, antiepileptic drugs (carbamazepine), antiparkinsonian drugs (levodopa), nitrates. Reduces the toxic effects of ethanol.
Pyridoxine
It enhances the effect of diuretics, weakens the activity of levodopa, is well combined with cardiac glycosides (pyridoxine increases the synthesis of contractile proteins in the myocardium), glutamic acid, potassium and magnesium asparaginate (increases resistance to hypoxia).
Pyridoxine is pharmacologically incompatible with thiamine and cyanocobalamin.
Isoniazid, penicillamine, cycloserine, and estrogen-containing oral contraceptives weaken the effect of pyridoxine.
Round, biconvex tablets, covered with a film shell of white or almost white color.
On the cross section — white or almost white color.
Nausea, dry mouth, diarrhea, drowsiness, allergic reactions, hypersecretion of hydrochloric acid( HCl), numbness, the appearance of a feeling of compression in the extremities — a symptom of stockings and gloves, decreased lactation (sometimes this is used as a therapeutic effect).
By prescription.
Influence on the ability to drive vehicles and mechanisms. During the treatment period, it is necessary to be careful when driving vehicles and engaging in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.
As part of combination therapy for the following diseases and conditions:
dyscirculatory encephalopathy,
vegetative dystonia syndrome,
anxiety states in neurotic and neurosis-like states,
withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders,
coronary heart disease (prevention of seizures),
conditions after acute intoxication with antipsychotic drugs,
asthenic conditions, as well as prevention of the development of somatic diseases under the influence of extreme factors and loads,
the impact of extreme (stressful) factors.
Mexiv 6® - combined drug.
Ethylmethylhydroxypyridine succinate — inhibitor of free radical processes, a membrane protector, which also has antihypoxic, stress-protective, nootropic, antiepileptic and anxiolytic effects. An antioxidant drug that regulates metabolic processes in the myocardium and vascular wall.
The mechanism of action is due to the antioxidant and membrane protective properties. It suppresses lipid peroxidation, increases the activity of superoxidase, affects the physical and chemical properties of the membrane, increases the content of polar lipid fractions (in t.tsch. phosphotidylserine and phosphotidylinositol) in the membrane, reduces the cholesterol/phospholipid ratio, reduces the viscosity of the lipid layer and increases the fluidity of the membrane, activates the energy-synthesizing functions of mitochondria and improves energy metabolism in the cell and thus protects the cell apparatus and the structure of their membranes. The change in the functional activity of the biological membrane caused by the drug leads to conformational changes in the protein macromolecules of synaptic membranes, as a result of which it has a modulating effect on the activity of membrane-bound enzymes, ion channels and receptor complexes, in particular benzodiazepine, GABA, acetylcholine, enhancing their ability to bind to ligands, increasing the activity of neurotransmitters and activating synaptic processes. Increases the compensatory activation of aerobic glycolysis and reduces the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in ATP and creatine phosphate, activates the energy-synthesizing function of mitochondria. Increases the body's resistance to the effects of various damaging factors in pathological conditions (shock, hypoxia and ischemia, disorders of cerebral circulation, intoxication with ethanol and antipsychotic drugs). Improves the metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation
It stabilizes the membranes of blood cells (red blood cells and platelets), reducing the likelihood of hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and LDL. Improves the functional state of the ischemic myocardium, reducing the manifestations of systolic and diastolic dysfunction of the left ventricle, as well as electrical instability of the myocardium.
In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes PDE, adenylate cyclase, and acetylcholinesterase. Supports the activation of aerobic glycolysis that develops in acute ischemia and promotes the restoration of mitochondrial redox processes in hypoxia, increases the synthesis of ATP, creatine phosphate and other macroergs. Increases the collateral blood supply to the ischemic myocardium and activates the energy-synthesizing processes in the ischemic area, which contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity
In patients with stable angina pectoris, it increases exercise tolerance and antianginal activity of nitrates, improves the rheological properties of blood, and reduces the incidence of acute coronary insufficiency.
Pyridoxine Upon entering the body, it is phosphorylated, converted to pyridoxal-5-phosphate and is part of the enzymes that perform decarboxylation, transamination and racemization of amino acids, as well as the enzymatic conversion of sulfur-containing and hydroxylated amino acids. Participates in the metabolism, is necessary for the normal functioning of the central and peripheral nervous system. Pyridoxine is involved in the metabolism of tryptophan, methionine, cysteine, glutamic and other amino acids. It plays an important role in the exchange of histamine. Promotes the normalization of lipid metabolism.
Ethylmethylhydroxypyridine succinate it is rapidly absorbed when taken orally (the half-absorption period is 0.08-1 h). Cmax when taken orally-50-100 ng / ml, Tmax - 0.46-0.5 h. Quickly distributed in organs and tissues. The average retention time of ethylmethylhydroxypyridine succinate in the body when taken orally is 4.9–5.2 hours. Ethylmethylhydroxypyridine succinate is metabolized in the liver by glucuronidation.
5 metabolites were identified: 3-oxypyridine phosphate-is formed in the liver and with the participation of alkaline phosphatase breaks down into phosphoric acid and 3-oxypyridine, the 2nd metabolite-pharmacologically active, is formed in large quantities and is detected in the urine on day 1-2 after administration, the 3rd — is excreted in large quantities in the urine, the 4th and 5th-glucuronconjugates.
T1/2 when taken orally-4.7-5 hours. It is rapidly excreted in the urine mainly in the form of metabolites (50% in 12 hours) and in a small amount-in unchanged form (0.3% in 12 hours). It is most intensively excreted during the first 4 hours after taking ethylmethylhydroxypyridine succinate. Indicators of urinary excretion of unchanged ethylmethylhydroxypyridine succinate and metabolites have significant individual variability.
Pyridoxine it is absorbed quickly throughout the small intestine. It is metabolized in the liver to form pharmacologically active metabolites (pyridoxal phosphate and pyridoxaminophosphate). Pyridoxal phosphate binds to plasma proteins by 90%. It penetrates well into all tissues, accumulates mainly in the liver, less-in the muscles and central nervous system. Penetrates through the placenta, secreted with breast milk. T1/2 - 15-20 days. It is excreted by the kidneys (with intravenous administration - with bile 2%), as well as during hemodialysis.
At a temperature not exceeding 25 °C, in the original packaging.
Keep out of reach of children.
Shelf life of the drug MeksiV 6®2 года.Do not use after the expiration date indicated on the package.
| Film-coated tablets | 1 table. |
| active ingredients: | |
| ethylmethylhydroxypyridine succinate | 125 mg |
| pyridoxine hydrochloride | 10 mg |
| excipients: calcium hydrophosphate dihydrate-65 mg, calcium stearate-6.7 mg, copovidone-14 mg, silicon dioxide colloidal-20 mg, croscarmellose sodium-20 mg, magnesium lactate dihydrate-327.6 mg, magnesium stearate-6.7 mg, castor oil hydrogenated-5 mg, MCC-50 mg | |
| film shell: Opadry white (hypromellose (hydroxypropyl-methylcellulose) - 6.75 mg, hyprolose (hydroxypropylcellulose) - 6.75 mg, talc-4 mg, titanium dioxide-2.5 mg) — 20 mg |
Film-coated tablets. 10 or 15 tables in a contour cell package made of PVC film and aluminum foil printed lacquered. For 1, 2, 3, 6, 10 contour cell packages for 10 tables. or 1, 2, 4, 6 contour cell packages of 15 tables are placed in a pack of cardboard.
Inside, 1 tablet 3 times a day, the initial dose-1-2 tablets 1-2 times a day with a gradual increase until a therapeutic effect is obtained. The maximum daily dose is 6 tablets/day. The duration of treatment is 2-8 weeks. If necessary, it is possible to conduct repeated courses.
N07XX Other drugs for the treatment of diseases of the nervous system
